Lute Scott, Aranha Hazel, Tremblay Denise, Liang Dehai, Ackermann Hans-W, Chu Benjamin, Moineau Sylvain, Brorson Kurt
Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, 29 Lincoln Dr., Bethesda, MD 20892, USA.
Appl Environ Microbiol. 2004 Aug;70(8):4864-71. doi: 10.1128/AEM.70.8.4864-4871.2004.
Virus filtration is a key clearance unit operation in the manufacture of recombinant protein, monoclonal antibody, and plasma-derived biopharmaceuticals. Recently, a consensus has developed among filter manufacturers and end users about the desirability of a common nomenclature and a standardized test for classifying and identifying virus-retentive filters. The Parenteral Drug Association virus filter task force has chosen PR772 as the model bacteriophage to standardize nomenclature for large-pore-size virus-retentive filters (filters designed to retain viruses larger than 50 to 60 nm in size). Previously, the coliphage PR772 (Tectiviridae family) has been used in some filtration studies as a surrogate for mammalian viruses of around 50 to 60 nm. In this report, we describe specific properties of PR772 critical to the support of its use for the standardization of virus filters. The complete genomic sequence of virulent phage PR772 was determined. Its genome contains 14,946 bp with an overall G+C content of 48.3 mol%, and 32 open reading frames of at least 40 codons. Comparison of the PR772 nucleotide sequence with the genome of Tectiviridae family prototype phage PRD1 revealed 97.2% identity at the DNA level. By dynamic light-scattering analysis, its hydrodynamic diameter was measured as 82 +/- 6 nm, consistent with use in testing large-virus-retentive filters. Finally, dynamic light-scattering analysis of PR772 preparations purified on CsCl gradients showed that the phage preparations are largely monodispersed. In summary, PR772 appears to be an appropriate model bacteriophage for standardization of nomenclature for larger-pore-size virus-retentive filters.
病毒过滤是重组蛋白、单克隆抗体和血浆衍生生物制药生产中的关键清除单元操作。最近,过滤器制造商和终端用户已就通用命名法和用于分类与识别病毒截留过滤器的标准化测试达成共识。胃肠外药物协会病毒过滤特别工作组已选择PR772作为模型噬菌体,以标准化大孔径病毒截留过滤器(设计用于截留尺寸大于50至60 nm病毒的过滤器)的命名法。此前,大肠杆菌噬菌体PR772( tectiviridae家族)已在一些过滤研究中用作约50至60 nm哺乳动物病毒的替代物。在本报告中,我们描述了PR772对于支持其用于病毒过滤器标准化至关重要的特定特性。测定了烈性噬菌体PR772的完整基因组序列。其基因组包含14,946 bp,总体G + C含量为48.3 mol%,以及32个至少40个密码子的开放阅读框。将PR772核苷酸序列与tectiviridae家族原型噬菌体PRD1的基因组进行比较,发现DNA水平上的同一性为97.2%。通过动态光散射分析,测得其流体动力学直径为82 +/- 6 nm,这与在测试大病毒截留过滤器中的使用一致。最后,对在CsCl梯度上纯化的PR772制剂进行动态光散射分析表明,噬菌体制剂在很大程度上是单分散的。总之,PR772似乎是用于标准化大孔径病毒截留过滤器命名法的合适模型噬菌体。